Logo image of SGTX

SIGILON THERAPEUTICS INC (SGTX) Stock Fundamental Analysis

NASDAQ:SGTX - Nasdaq - US82657L2060 - Common Stock - Currency: USD

22.47  -0.59 (-2.56%)

After market: 23 +0.53 (+2.36%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SGTX. SGTX was compared to 562 industry peers in the Biotechnology industry. Both the profitability and financial health of SGTX have multiple concerns. SGTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SGTX has reported negative net income.
In the past year SGTX has reported a negative cash flow from operations.
In the past 5 years SGTX always reported negative net income.
SGTX had negative operating cash flow in 4 of the past 5 years.
SGTX Yearly Net Income VS EBIT VS OCF VS FCFSGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 20M -20M -40M -60M -80M

1.2 Ratios

SGTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SGTX Yearly ROA, ROE, ROICSGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K -2.5K

1.3 Margins

SGTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGTX Yearly Profit, Operating, Gross MarginsSGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -200 -400 -600 -800

More info and screens

2

2. Health

2.1 Basic Checks

SGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SGTX has been increased compared to 1 year ago.
Compared to 1 year ago, SGTX has a worse debt to assets ratio.
SGTX Yearly Shares OutstandingSGTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
SGTX Yearly Total Debt VS Total AssetsSGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.91, we must say that SGTX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SGTX (-4.91) is worse than 68.20% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that SGTX is not too dependend on debt financing.
SGTX's Debt to Equity ratio of 0.31 is on the low side compared to the rest of the industry. SGTX is outperformed by 73.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -4.91
ROIC/WACCN/A
WACC9.94%
SGTX Yearly LT Debt VS Equity VS FCFSGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

SGTX has a Current Ratio of 2.23. This indicates that SGTX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.23, SGTX is not doing good in the industry: 80.27% of the companies in the same industry are doing better.
A Quick Ratio of 2.23 indicates that SGTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.23, SGTX is doing worse than 78.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.23
SGTX Yearly Current Assets VS Current LiabilitesSGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

SGTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -327.88%.
The Revenue has grown by 49.27% in the past year. This is a very strong growth!
SGTX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.95% yearly.
EPS 1Y (TTM)-327.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.35%
Revenue 1Y (TTM)49.27%
Revenue growth 3Y-2.95%
Revenue growth 5YN/A
Sales Q2Q%53.49%

3.2 Future

SGTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.31% yearly.
The Revenue is expected to decrease by -0.28% on average over the next years.
EPS Next Y-34.47%
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%
EPS Next 5Y13.31%
Revenue Next Year19.62%
Revenue Next 2Y10.18%
Revenue Next 3Y6.68%
Revenue Next 5Y-0.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SGTX Yearly Revenue VS EstimatesSGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M
SGTX Yearly EPS VS EstimatesSGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGTX Price Earnings VS Forward Price EarningsSGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGTX Per share dataSGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

A cheap valuation may be justified as SGTX's earnings are expected to decrease with -16.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIGILON THERAPEUTICS INC

NASDAQ:SGTX (8/10/2023, 8:02:09 PM)

After market: 23 +0.53 (+2.36%)

22.47

-0.59 (-2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-02 2023-08-02/amc
Earnings (Next)11-08 2023-11-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners80.43%
Ins Owner Change0%
Market Cap56.50M
Analysts80
Price Target48.28 (114.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.03%
Min EPS beat(2)0.52%
Max EPS beat(2)45.53%
EPS beat(4)4
Avg EPS beat(4)21.01%
Min EPS beat(4)0.26%
Max EPS beat(4)45.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)25.42%
Min Revenue beat(2)-2.79%
Max Revenue beat(2)53.64%
Revenue beat(4)3
Avg Revenue beat(4)32.66%
Min Revenue beat(4)-2.79%
Max Revenue beat(4)66.75%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1013.72%
EPS NQ rev (1m)0.21%
EPS NQ rev (3m)-1950%
EPS NY rev (1m)-1057.2%
EPS NY rev (3m)-1057.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.1%
Revenue NY rev (1m)27.67%
Revenue NY rev (3m)27.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.86
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 1.7
EV/EBITDA N/A
EPS(TTM)-9.67
EYN/A
EPS(NY)-13.12
Fwd EYN/A
FCF(TTM)-17.45
FCFYN/A
OCF(TTM)-17.26
OCFYN/A
SpS5.82
BVpS13.24
TBVpS13.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 2.23
Altman-Z -4.91
F-Score2
WACC9.94%
ROIC/WACCN/A
Cap/Depr(3y)106.78%
Cap/Depr(5y)188.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-327.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.35%
EPS Next Y-34.47%
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%
EPS Next 5Y13.31%
Revenue 1Y (TTM)49.27%
Revenue growth 3Y-2.95%
Revenue growth 5YN/A
Sales Q2Q%53.49%
Revenue Next Year19.62%
Revenue Next 2Y10.18%
Revenue Next 3Y6.68%
Revenue Next 5Y-0.28%
EBIT growth 1Y46.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.02%
EBIT Next 3Y8.16%
EBIT Next 5YN/A
FCF growth 1Y37.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.23%
OCF growth 3YN/A
OCF growth 5YN/A